Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer
- Registration Number
- NCT00003677
- Lead Sponsor
- M.D. Anderson Cancer Center
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients who have metastatic pancreatic cancer.
- Detailed Description
OBJECTIVES: I. Assess the antitumor activity of dolastatin 10 in patients with metastatic adenocarcinoma of the pancreas. II. Evaluate the qualitative and quantitative toxic effects of this therapy in these patients. III. Investigate the clinical pharmacology of this treatment.
OUTLINE: This is an open label, multicenter study. Patients receive dolastatin 10 IV bolus once every 21 days. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months until death.
PROJECTED ACCRUAL: This study will accrue 12-37 patients within 18.5 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 9
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Dolastatin 10 Dolastatin 10 Dolastatin 10 IV bolus once every 21 days.
- Primary Outcome Measures
Name Time Method Number of Patients with Toxicity Every 3 months Toxic effects of dolastatin 10 therapy in patients with metastatic adenocarcinoma of the pancreas used to assess antitumor activity.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
University of Texas - MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
University of Chicago Cancer Research Center
🇺🇸Chicago, Illinois, United States